Stock Taper 
VOGX
$29.52
▲ UP 24.82% (5.87)
KEY STATISTICS
Market Cap$0.00
52w High$29.64
52w Low$12.95
Dividend Yield—
Frequency—
P/E—
Volume428.74K
Shares Out.—
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
James Green
ABOUT
SECTOR
Healthcare
WENT PUBLIC
August 12, 2026
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
4
PRICE
$29.52 ▲ UP 24.82% (+$5.87)About Vogenx Inc.
https://www.vogenx.com ↗Vogenx is a clinical-stage biopharmaceutical company developing novel therapeutics, including mizagliflozin, for serious metabolic disorders like post-bariatric hypoglycemia and gastroparesis.
INDUSTRY
Biotechnology
A PRODUCT VOGENX INC. IS KNOWN FOR
Mizagliflozin
Mizagliflozin, Vogenx Inc.'s Phase 2 oral drug candidate, targets metabolic and gastrointestinal diseases like PBH and gastroparesis by inhibiting SGLT1, representing a novel first-in-class treatment approach.
